Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

"Omics" data integration and functional analyses link Enoyl-CoA hydratase, short chain 1 to drug refractory dilated cardiomyopathy.

Campbell NV, Weitzenkamp DA, Campbell IL, Schmidt RF, Hicks C, Morgan MJ, Irwin DC, Tentler JJ.

BMC Med Genomics. 2018 Dec 12;11(1):110. doi: 10.1186/s12920-018-0439-6.

2.

Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma.

Sinik L, Minson KA, Tentler JJ, Carrico J, Bagby SM, Robinson WA, Kami R, Burstyn-Cohen T, Eckhardt SG, Wang X, Frye SV, Earp HS, DeRyckere D, Graham DK.

Mol Cancer Ther. 2019 Feb;18(2):278-288. doi: 10.1158/1535-7163.MCT-18-0456. Epub 2018 Nov 27.

PMID:
30482852
3.

BRAF fusions identified in melanomas have variable treatment responses and phenotypes.

Turner JA, Bemis JGT, Bagby SM, Capasso A, Yacob BW, Chimed TS, Van Gulick R, Lee H, Tobin R, Tentler JJ, Pitts T, McCarter M, Robinson WA, Couts KL.

Oncogene. 2019 Feb;38(8):1296-1308. doi: 10.1038/s41388-018-0514-7. Epub 2018 Sep 25.

PMID:
30254212
4.

A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer.

Diamond JR, Eckhardt SG, Pitts TM, van Bokhoven A, Aisner D, Gustafson DL, Capasso A, Sams S, Kabos P, Zolman K, Colvin T, Elias AD, Storniolo AM, Schneider BP, Gao D, Tentler JJ, Borges VF, Miller KD.

Breast Cancer Res. 2018 Aug 2;20(1):82. doi: 10.1186/s13058-018-1014-y.

5.

Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models.

Capasso A, Pitts TM, Klauck PJ, Bagby SM, Westbrook L, Kaplan J, Soleimani M, Spreafico A, Tentler JJ, Diamond JR, Arcaroli JJ, Messersmith WA, Eckhardt SG, Leong S.

Anticancer Drugs. 2018 Oct;29(9):827-838. doi: 10.1097/CAD.0000000000000673.

6.

Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer.

Klauck PJ, Bagby SM, Capasso A, Bradshaw-Pierce EL, Selby HM, Spreafico A, Tentler JJ, Tan AC, Kim J, Arcaroli JJ, Purkey A, Messersmith WA, Kuida K, Eckhardt SG, Pitts TM.

BMC Cancer. 2018 Feb 5;18(1):136. doi: 10.1186/s12885-018-4036-z.

7.

ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms.

Couts KL, Bemis J, Turner JA, Bagby SM, Murphy D, Christiansen J, Hintzsche JD, Le A, Pitts TM, Wells K, Applegate A, Amato C, Multani P, Chow-Maneval E, Tentler JJ, Shellman YG, Rioth MJ, Tan AC, Gonzalez R, Medina T, Doebele RC, Robinson WA.

Mol Cancer Ther. 2018 Jan;17(1):222-231. doi: 10.1158/1535-7163.MCT-17-0472. Epub 2017 Oct 20.

8.

Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer.

Ionkina AA, Tentler JJ, Kim J, Capasso A, Pitts TM, Ryall KA, Howison RR, Kabos P, Sartorius CA, Tan AC, Eckhardt SG, Diamond JR.

Front Oncol. 2017 May 15;7:94. doi: 10.3389/fonc.2017.00094. eCollection 2017.

9.

Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma.

Hintzsche JD, Gorden NT, Amato CM, Kim J, Wuensch KE, Robinson SE, Applegate AJ, Couts KL, Medina TM, Wells KR, Wisell JA, McCarter MD, Box NF, Shellman YG, Gonzalez RC, Lewis KD, Tentler JJ, Tan AC, Robinson WA.

Melanoma Res. 2017 Jun;27(3):189-199. doi: 10.1097/CMR.0000000000000345.

10.

Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).

Wong KM, Micel LN, Selby HM, Tan AC, Pitts TM, Bagby SM, Spreafico A, Klauck PJ, Blakemore SJ, Smith PF, McDonald A, Berger A, Tentler JJ, Eckhardt SG.

Invest New Drugs. 2017 Feb;35(1):11-25. doi: 10.1007/s10637-016-0398-8. Epub 2016 Oct 25.

11.

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies.

Bagby S, Messersmith WA, Pitts TM, Capasso A, Varella-Garcia M, Klauck PJ, Kim J, Tan AC, Eckhardt SG, Tentler JJ, Arcaroli J.

J Vis Exp. 2016 Sep 30;(115). doi: 10.3791/54393.

12.

Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.

Pitts TM, Bradshaw-Pierce EL, Bagby SM, Hyatt SL, Selby HM, Spreafico A, Tentler JJ, McPhillips K, Klauck PJ, Capasso A, Diamond JR, Davis SL, Tan AC, Arcaroli JJ, Purkey A, Messersmith WA, Ecsedy JA, Eckhardt SG.

Oncotarget. 2016 Aug 2;7(31):50290-50301. doi: 10.18632/oncotarget.10366.

13.

An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer.

Ryall KA, Kim J, Klauck PJ, Shin J, Yoo M, Ionkina A, Pitts TM, Tentler JJ, Diamond JR, Eckhardt SG, Heasley LE, Kang J, Tan AC.

BMC Genomics. 2015;16 Suppl 12:S2. doi: 10.1186/1471-2164-16-S12-S2. Epub 2015 Dec 9.

14.

Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.

Lieu CH, Klauck PJ, Henthorn PK, Tentler JJ, Tan AC, Spreafico A, Selby HM, Britt BC, Bagby SM, Arcaroli JJ, Messersmith WA, Pitts TM, Eckhardt SG.

Oncotarget. 2015 Oct 27;6(33):34561-72. doi: 10.18632/oncotarget.5949.

15.

Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models.

Davis SL, Robertson KM, Pitts TM, Tentler JJ, Bradshaw-Pierce EL, Klauck PJ, Bagby SM, Hyatt SL, Selby HM, Spreafico A, Ecsedy JA, Arcaroli JJ, Messersmith WA, Tan AC, Eckhardt SG.

Front Pharmacol. 2015 Jun 16;6:120. doi: 10.3389/fphar.2015.00120. eCollection 2015.

16.

p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer.

Tentler JJ, Ionkina AA, Tan AC, Newton TP, Pitts TM, Glogowska MJ, Kabos P, Sartorius CA, Sullivan KD, Espinosa JM, Eckhardt SG, Diamond JR.

Mol Cancer Ther. 2015 May;14(5):1117-29. doi: 10.1158/1535-7163.MCT-14-0538-T. Epub 2015 Mar 10.

17.

Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer.

Pitts TM, Newton TP, Bradshaw-Pierce EL, Addison R, Arcaroli JJ, Klauck PJ, Bagby SM, Hyatt SL, Purkey A, Tentler JJ, Tan AC, Messersmith WA, Eckhardt SG, Leong S.

PLoS One. 2014 Nov 17;9(11):e113037. doi: 10.1371/journal.pone.0113037. eCollection 2014.

18.

Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants.

Micel LN, Tentler JJ, Tan AC, Selby HM, Brunkow KL, Robertson KM, Davis SL, Klauck PJ, Pitts TM, Gangolli E, Fabrey R, O'Connell SM, Vincent PW, Eckhardt SG.

Mol Cancer Ther. 2015 Feb;14(2):317-25. doi: 10.1158/1535-7163.MCT-13-1012. Epub 2014 Nov 5.

19.

Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers.

Davis SL, Eckhardt SG, Tentler JJ, Diamond JR.

Ther Adv Med Oncol. 2014 May;6(3):88-100. doi: 10.1177/1758834013519843. Review.

20.

Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.

Flanigan SA, Pitts TM, Newton TP, Kulikowski GN, Tan AC, McManus MC, Spreafico A, Kachaeva MI, Selby HM, Tentler JJ, Eckhardt SG, Leong S.

Clin Cancer Res. 2013 Nov 15;19(22):6219-29. doi: 10.1158/1078-0432.CCR-13-0145. Epub 2013 Sep 17.

21.

Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer.

Spreafico A, Tentler JJ, Pitts TM, Tan AC, Gregory MA, Arcaroli JJ, Klauck PJ, McManus MC, Hansen RJ, Kim J, Micel LN, Selby HM, Newton TP, McPhillips KL, Gustafson DL, Degregori JV, Messersmith WA, Winn RA, Eckhardt SG.

Clin Cancer Res. 2013 Aug 1;19(15):4149-62. doi: 10.1158/1078-0432.CCR-12-3140. Epub 2013 Jun 11.

22.

MERTK receptor tyrosine kinase is a therapeutic target in melanoma.

Schlegel J, Sambade MJ, Sather S, Moschos SJ, Tan AC, Winges A, DeRyckere D, Carson CC, Trembath DG, Tentler JJ, Eckhardt SG, Kuan PF, Hamilton RL, Duncan LM, Miller CR, Nikolaishvili-Feinberg N, Midkiff BR, Liu J, Zhang W, Yang C, Wang X, Frye SV, Earp HS, Shields JM, Graham DK.

J Clin Invest. 2013 May;123(5):2257-67. doi: 10.1172/JCI67816. Epub 2013 Apr 15.

23.

Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models.

Pitts TM, Kulikowski GN, Tan AC, Murray BW, Arcaroli JJ, Tentler JJ, Spreafico A, Selby HM, Kachaeva MI, McPhillips KL, Britt BC, Bradshaw-Pierce EL, Messersmith WA, Varella-Garcia M, Eckhardt SG.

Front Pharmacol. 2013 Mar 28;4:35. doi: 10.3389/fphar.2013.00035. eCollection 2013.

24.

Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies.

Micel LN, Tentler JJ, Smith PG, Eckhardt GS.

J Clin Oncol. 2013 Mar 20;31(9):1231-8. doi: 10.1200/JCO.2012.44.0958. Epub 2013 Jan 28. Review.

25.

CtBP1 is expressed in melanoma and represses the transcription of p16INK4a and Brca1.

Deng H, Liu J, Deng Y, Han G, Shellman YG, Robinson SE, Tentler JJ, Robinson WA, Norris DA, Wang XJ, Zhang Q.

J Invest Dermatol. 2013 May;133(5):1294-301. doi: 10.1038/jid.2012.487. Epub 2013 Jan 10.

26.

Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models.

Diamond JR, Eckhardt SG, Tan AC, Newton TP, Selby HM, Brunkow KL, Kachaeva MI, Varella-Garcia M, Pitts TM, Bray MR, Fletcher GC, Tentler JJ.

Clin Cancer Res. 2013 Jan 1;19(1):291-303. doi: 10.1158/1078-0432.CCR-12-1611. Epub 2012 Nov 7.

27.

ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53.

Sullivan KD, Padilla-Just N, Henry RE, Porter CC, Kim J, Tentler JJ, Eckhardt SG, Tan AC, DeGregori J, Espinosa JM.

Nat Chem Biol. 2012 Jul;8(7):646-54. doi: 10.1038/nchembio.965. Epub 2012 Jun 3.

28.

Patient-derived tumour xenografts as models for oncology drug development.

Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, Arcaroli JJ, Messersmith WA, Eckhardt SG.

Nat Rev Clin Oncol. 2012 Apr 17;9(6):338-50. doi: 10.1038/nrclinonc.2012.61. Review.

29.

Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.

Morelli MP, Tentler JJ, Kulikowski GN, Tan AC, Bradshaw-Pierce EL, Pitts TM, Brown AM, Nallapareddy S, Arcaroli JJ, Serkova NJ, Hidalgo M, Ciardiello F, Eckhardt SG.

Clin Cancer Res. 2012 Feb 15;18(4):1051-62. doi: 10.1158/1078-0432.CCR-11-1507. Epub 2011 Dec 15.

30.

Mapping of ESE-1 subdomains required to initiate mammary epithelial cell transformation via a cytoplasmic mechanism.

Prescott JD, Poczobutt JM, Tentler JJ, Walker DM, Gutierrez-Hartmann A.

Mol Cancer. 2011 Aug 28;10:103. doi: 10.1186/1476-4598-10-103.

31.

Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines.

Spratlin JL, Pitts TM, Kulikowski GN, Morelli MP, Tentler JJ, Serkova NJ, Eckhardt SG.

Anticancer Res. 2011 Apr;31(4):1093-103.

32.

The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models.

Flanigan SA, Pitts TM, Eckhardt SG, Tentler JJ, Tan AC, Thorburn A, Leong S.

Clin Cancer Res. 2010 Nov 15;16(22):5436-46. doi: 10.1158/1078-0432.CCR-10-2054. Epub 2010 Oct 13.

33.

Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.

Tentler JJ, Nallapareddy S, Tan AC, Spreafico A, Pitts TM, Morelli MP, Selby HM, Kachaeva MI, Flanigan SA, Kulikowski GN, Leong S, Arcaroli JJ, Messersmith WA, Eckhardt SG.

Mol Cancer Ther. 2010 Dec;9(12):3351-62. doi: 10.1158/1535-7163.MCT-10-0376. Epub 2010 Oct 5.

34.

Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development.

Pitts TM, Tan AC, Kulikowski GN, Tentler JJ, Brown AM, Flanigan SA, Leong S, Coldren CD, Hirsch FR, Varella-Garcia M, Korch C, Eckhardt SG.

Clin Cancer Res. 2010 Jun 15;16(12):3193-204. doi: 10.1158/1078-0432.CCR-09-3191. Epub 2010 Jun 8.

35.

Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models.

Tentler JJ, Bradshaw-Pierce EL, Serkova NJ, Hasebroock KM, Pitts TM, Diamond JR, Fletcher GC, Bray MR, Eckhardt SG.

Clin Cancer Res. 2010 Jun 1;16(11):2989-2998. doi: 10.1158/1078-0432.CCR-10-0325. Epub 2010 Apr 20.

36.

Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines.

Morelli MP, Brown AM, Pitts TM, Tentler JJ, Ciardiello F, Ryan A, Jürgensmeier JM, Eckhardt SG.

Mol Cancer Ther. 2009 Sep;8(9):2546-58. doi: 10.1158/1535-7163.MCT-09-0380. Epub 2009 Sep 15.

37.

Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models.

Pitts TM, Morrow M, Kaufman SA, Tentler JJ, Eckhardt SG.

Mol Cancer Ther. 2009 Feb;8(2):342-9. doi: 10.1158/1535-7163.MCT-08-0534. Epub 2009 Jan 27.

38.

Structural and functional analysis of the differential effects of c-Jun and v-Jun on prolactin gene expression.

Farrow KN, Bradford AP, Tentler JJ, Gutierrez-Hartmann A.

Mol Endocrinol. 2004 Oct;18(10):2479-90. Epub 2004 Jul 1.

PMID:
15231872
39.

ESX induces transformation and functional epithelial to mesenchymal transition in MCF-12A mammary epithelial cells.

Schedin PJ, Eckel-Mahan KL, McDaniel SM, Prescott JD, Brodsky KS, Tentler JJ, Gutierrez-Hartmann A.

Oncogene. 2004 Mar 4;23(9):1766-79.

PMID:
14767472
40.

The epithelial-specific ETS transcription factor ESX/ESE-1/Elf-3 modulates breast cancer-associated gene expression.

Eckel KL, Tentler JJ, Cappetta GJ, Diamond SE, Gutierrez-Hartmann A.

DNA Cell Biol. 2003 Feb;22(2):79-94.

PMID:
12713734
41.

Selective repression of rat prolactin gene by stable expression of dominant-negative Ets in GH4 pituitary cells.

Tentler JJ, Bradford AP, Schweppe RE, Gutierrez-Hartmann A.

Endocrine. 2003 Feb-Mar;20(1-2):3-12.

PMID:
12668863
43.

Ethanol, growth hormone and testosterone in peripubertal rats.

Tentler JJ, LaPaglia N, Steiner J, Williams D, Castelli M, Kelley MR, Emanuele NV, Emanuele MA.

J Endocrinol. 1997 Mar;152(3):477-87.

PMID:
9071969
44.

Further characterization of the impact of ethanol on βLH: alterations in polyribosome association of βLH mRNA.

Halloran MM, Emanuele MA, Emanuele NV, Tentler JJ, Kelley MR.

Endocrine. 1995 Jun;3(6):469-73. doi: 10.1007/BF02935654.

PMID:
21153252
45.

Acute ethanol exposure suppresses the repair of O6-methylguanine DNA lesions in castrated adult male rats.

Wilson DM 3rd, Tentler JJ, Carney JP, Wilson TM, Kelley MR.

Alcohol Clin Exp Res. 1994 Oct;18(5):1267-71.

PMID:
7847618
46.

The effects of ethanol on pituitary function.

Emanuele MA, Halloran MM, Tentler JJ, Uddin S, Emanuele NV, Kelley MR.

Compr Ther. 1994;20(6):326-30. Review. No abstract available.

PMID:
8062540
47.

Failure of ethanol to induce changes in gonadotropin gene expression in selectively bred ethanol-sensitive rats.

Halloran MM, Emanuele MA, Draski L, Tentler JJ, Emanuele NV, Kelley MR.

Endocr Res. 1993 Dec;19(4):317-29.

PMID:
8306944
48.

The effect of "binge" ethanol exposure on growth hormone and prolactin gene expression and secretion.

Emanuele MA, Tentler JJ, Kirsteins L, Emanuele NV, Lawrence A, Kelley MR.

Endocrinology. 1992 Nov;131(5):2077-82.

PMID:
1330488
49.

The effect of acute in vivo ethanol exposure on follicle stimulating hormone transcription and translation.

Emanuele MA, Tentler JJ, Halloran MM, Emanuele NV, Wallock L, Kelley MR.

Alcohol Clin Exp Res. 1992 Aug;16(4):776-80.

PMID:
1530142
50.

The rat prolactin gene is expressed in brain tissue: detection of normal and alternatively spliced prolactin messenger RNA.

Emanuele NV, Jurgens JK, Halloran MM, Tentler JJ, Lawrence AM, Kelley MR.

Mol Endocrinol. 1992 Jan;6(1):35-42.

PMID:
1738369

Supplemental Content

Loading ...
Support Center